BridgeBio Pharma Inc. Common Stock (BBIO)
Stock · NASDAQ · Health Care
$76.6as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$67.81
Industry
Biotechnology: Pharmaceutical Preparations
About BBIO
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for t…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 999
- Website
- bridgebio.com/
Fundamentals
- 1-day range
- $76.34$80.55
- Market cap
- $15.65B
- P/E (trailing)
- —
- P/E (forward)
- 500.07
- EPS (trailing)
- $-3.75
- Dividend yield
- —
- Beta
- 0.94
- Avg. volume
- 3.23M
52-week range
$48.78$93.42
Next earnings: October 28, 2026 · EPS estimate $-0.67confirmed
How BridgeBio Pharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
21 analyst ratings
Buy 89%
Hold 11%
Sell 0%
1-year price forecast
High
$157
+105.0%
Median
$108
+41.0%
Low
$80
+4.4%
BridgeBio Pharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BBIOBridgeBio Pharma Inc. Common Stock$76.62▼ 2.62%Market cap $15.65BP/E —$48.78$93.42
- JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$244.6▼ 2.59%Market cap $15.80BP/E 16.97$123.88$266.38
- ASNDAscendis Pharma A/S Ordinary Share$248.06▼ 0.52%Market cap $15.09BP/E 26.94$186.05$282.15
- ELANElanco Animal Health Incorporated Common Stock$24.12▼ 1.51%Market cap $12.85BP/E —$17.11$27.98
- MDGLMadrigal Pharmaceuticals Inc. Common Stock$534.12▼ 1.76%Market cap $11.14BP/E —$393.61$615
- AXSMAxsome Therapeutics Inc. Common Stock$199.01▼ 3.52%Market cap $10.86BP/E —$112.9$260.19
- VTRSViatris Inc. Common Stock$16.34▼ 3.26%Market cap $20.53BP/E —$9.43$18.39
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BBIO BridgeBio Pharma Inc. Common Stock | $15.65B | — | $76.62 | ▼ 2.62% | $48.78$93.42 |
| JAZZ Jazz Pharmaceuticals plc Common Stock (Ireland) | $15.80B | 16.97 | $244.6 | ▼ 2.59% | $123.88$266.38 |
| ASND Ascendis Pharma A/S Ordinary Share | $15.09B | 26.94 | $248.06 | ▼ 0.52% | $186.05$282.15 |
| ELAN Elanco Animal Health Incorporated Common Stock | $12.85B | — | $24.12 | ▼ 1.51% | $17.11$27.98 |
| MDGL Madrigal Pharmaceuticals Inc. Common Stock | $11.14B | — | $534.12 | ▼ 1.76% | $393.61$615 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.86B | — | $199.01 | ▼ 3.52% | $112.9$260.19 |
| VTRS Viatris Inc. Common Stock | $20.53B | — | $16.34 | ▼ 3.26% | $9.43$18.39 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- BridgeBio Pharma Doses First Patient In ASCEND-ATTR Trial To Evaluate Effects Of Acoramidis To Enhance Cardiac Structure, Function, And Amyloid Burden In Individuals With Transthyretin Amyloid Cardiomyopathybenzinga · 8/26/2026
- BridgeBio Pharma Doses First Patient In ASCEND-ATTR Trial To Evaluate Effects Of Acoramidis To Enhance Cardiac Structure, Function, And Amyloid Burden In Individuals With Transthyretin Amyloid CardiomyopathyBenzinga · 8/26/2026
- BridgeBio Pharma To Present Two Oral Presentations, Three Posters On New Acoramidis Data In Individuals With Transthyretin Amyloid Cardiomyopathy At European Society Of Cardiology Congress 2026Benzinga · 8/24/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 8/21/2026
- BridgeBio Pharma Launches Secondary Public Offering Of 5M Shares Of Common Stock By Selling Stockholder KKR Genetic Disorder L.PBenzinga · 8/13/2026
- Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107Benzinga · 8/12/2026
- Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106Benzinga · 8/12/2026
- JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111Benzinga · 8/12/2026
- BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 MonthsSeekingAlpha · 8/11/2026
Insider Activity
Insider Actions →Acquired
213.5K
Disposed
209.3K
- Maricel Apuli · July 30, 2026 · Sale2.0K @ $80.06
- Andrea Ellis · July 9, 2026 · Option Exercise17.2K @ $16.75
- Andrea Ellis · July 9, 2026 · Sale17.2K @ $84
- Jennifer E. Cook · July 9, 2026 · Option Exercise17.2K @ $16.75
- Jennifer E. Cook · July 9, 2026 · Option Exercise112.4K @ $29
- Jennifer E. Cook · July 9, 2026 · Option Exercise19.0K @ $8.45
- Jennifer E. Cook · July 9, 2026 · Sale112.4K @ $90
- Jennifer E. Cook · July 9, 2026 · Sale36.2K @ $84
- Jennifer E. Cook · June 24, 2026 · Option Exercise17.2K @ $16.75
- Jennifer E. Cook · June 24, 2026 · Option Exercise20.0K @ $8.45
- Jennifer E. Cook · June 24, 2026 · Sale37.2K @ $70
- Jennifer E. Cook · June 23, 2026 · Sale2.2K @ $68.57
- Hannah Valantine · June 23, 2026 · Sale2.2K @ $68.57
- Ali J. Satvat · June 22, 2026 · Grant5.3K
- Jennifer E. Cook · June 22, 2026 · Grant5.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 195.68M
- Total value held
- $14.01B
- Institutional holders
- 452
Top holders this quarter
- Unknown14.21M
- Unknown13.26M
- Unknown13.18M
- Unknown11.84M
- Unknown9.37M
- Unknown7.76M
- Unknown5.89M
- Unknown5.09M
- Unknown4.94M
- Unknown4.93M
See the full, filterable feed with live charts on the MarketWall dashboard.